Bupivacaine hydrochloride 0.5% (marcaine, pfizer) (DrugBank: Bupivacaine)
8 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
46 | Malignant rheumatoid arthritis | 1 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
70 | Spinal stenosis | 0 |
96 | Crohn disease | 0 |
168 | Ehlers-Danlos syndrome | 0 |
226 | Interstitial cystitis with Hunners ulcer | 0 |
298 | Hereditary pancreatitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04361513 (ClinicalTrials.gov) | April 15, 2020 | 22/4/2020 | Genicular Nerve Block in Rheuamtoid Arthritis | Genicular Nerve Block in Rheumatoid Arthritis: a Prospective Randomized Clinical Trial | Pain;Joint Function Disorder;Inflammation | Drug: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer);Drug: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) | Sohag University | NULL | Completed | 18 Years | N/A | All | 64 | Phase 4 | Egypt |